30 results about "Blood derivatives" patented technology

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

Phthalocyanine analogues having an active group able to link the phthalocyanine t carriers molecules and phthalocyanine to carriers molecules and phthalocyanine analogues as phthalocyanine-carrier conjugates showing enhanced photodynamic properties, red shifted absorption characteristic, all useful for photodynamic therapy, are described.Photosensitizers themselves or the photosensitizers-carriers conjugates are useful compounds either for treatment of various infectious diseases, the in vivo eradication of micro-organisms as well as diseases characterized by cellular hyperproliferation, in particular tumours psoriasis, actinic keratosis, atheromas, endoarterial hyperplasia and prostate hyperplasia.The above compounds can be also useful for blood and blood derivatives sterilization and in vivo / vitro diagnostics.

The present invention is directed to metal-phthalocyanines of general formula (I) to the corresponding conjugates, the processes for their preparation and use in the photodynamic therapy of microbial infections (viral, bacterial and mycotic), tumor, pre-cancerous and proliferative pathologies and / or in the diagnosis, as well as for blood and blood derivatives sterilization

The present invention regards a biological material comprising: a) a liquid carrier comprising a viscous solution containing at least one natural and / or semisynthetic polysaccharide, and having a Dynamic viscosity measured at 20° C. and at shear rate of D=350 s−1, comprised between 100 and 250 c Poise and / or a Kinematic viscosity comprised between 99 and 248cSt (measured at the same conditions); b) a culture of mesenchymal stem cells, and / or c) a platelet-rich hemo-derivative. This type of material in form of viscous liquid is particularly suitable for the therapy of osteoarthrosis, ligament damage, in particular tendon and cartilage damage) and may be administered intra-articularly, intradermally or directly applied in situ without altering the properties of the mesenchymal stem cells and / or platelets contained therein.

The present invention is directed to metal-phthalocyanines of general formula (I) to the corresponding conjugates, the processes for their preparation and use in the photodynamic therapy of microbial infections (viral, bacterial and mycotic), tumor, pre-cancerous and proliferative pathologies and / or in the diagnosis, as well as for blood and blood derivatives sterilization.

The invention relates to a method for the determination of a cancer diagnostic / therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein / peptide biomarkers and drug-targets based on the measurement of protein / peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein / peptide biomarkers those which show a pronounced differential behavior between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein / peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein / peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behavior between healthy and cancerous sample proteomes; (c) validation of the candidate protein / peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and / or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein / peptide biomarkers those which show a mass-spectrometrically measurable and / or antibody-based assay detectable differential behavior between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein / peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself.

The present invention regards a biological material comprising: a) a liquid carrier comprising a viscous solution containing at least one natural and / or semisynthetic polysaccharide, and having a Dynamic viscosity measured at 20° C. and at shear rate of D=350 s−1, comprised between 100 and 250 c Poise and / or a Kinematic viscosity comprised between 99 and 248 cSt (measured at the same conditions); b) a culture of mesenchymal stem cells, and / or c) a platelet-rich hemo-derivative. This type of material in form of viscous liquid is particularly suitable for the therapy of osteoarthrosis, ligament damage, in particular tendon and cartilage damage) and may be administered intra-articularly, intradermally or directly applied in situ without altering the properties of the mesenchymal stem cells and / or platelets contained therein.

The invention provides prodrugs activated by RNA-dependent DNA-polymerases, and methods for treating hematological tumors, blood, and blood derivatives from patients affected by retroviral infections by administering the prodrugs. The invention also provides methods for the preparation of pharmaceutical compositions containing the prodrugs.

The present invention relates to pharmaceutical compositions comprising metal phthalocyanine analogues of formula (I) and metal chelating compounds having a good bioavailability and enhanced photoinactivation properties against Gram negative bacteria; and to their use for in vivolex vivo applications, such as blood and blood derivatives sterilization.

A filter for removing substances, including leukocytes and platelets by way of non-limiting example, from whole blood or from blood derivatives, the filter includes a casing containing a layered filter element, at least one layer of this latter being coated with polyurethane; this polyurethane has a number average molecular weight between 10,000 and 20,000 Dalton. A method for forming the layered filter element for a filter such as mentioned above, in which at least one layer of this filter element is impregnated with polyurethane by immersing it in a container of a mixture in which the polyurethane is present. This mixture includes a solution in which the polyurethane is dissolved in a polar solvent such as water.

The present invention relates to pharmaceutical compositions comprising metal phthalocyanine analogues of formula (I) and metal chelating compounds having a good bioavailability and enhanced photoinactivation properties against Gram negative bacteria; and to their use for in vivolex vivo applications, such as blood and blood derivatives sterilization.

The present invention provides an enyzmatic cycling assay for assessing the amount of homocysteine and / or cystathionine in a solution such as blood, blood derivatives, or urine. The assay comprises the steps of contacting the solution containing homocysteine and / or cystathionine to form a reaction mixture, with CBS, or a derivative thereof, L-serine, and CBL, or a derivative thereof, for a time period sufficient to catalyze the cyclical conversion of homocysteine form to cystathionine and the reconversion of cystathionine to homocysteine with the production of pyruvate and ammonia; determiningthe amount of homocysteine and / or ammonia present in the reaction mixture; and determining the amount of homocysteine and / or cystathionine present in the solution based on the amount of pyruvate and / or ammonia formed. Expression vectors and isolation procedures for CBS, or derivatives thereof, and CBI, or derivatives thereof, are also provided as well as test kits for carrying out the assay. In preferred embodiments, the assays can be conducted in 15 minutes or less, with a minimum of enzyme usage.

A filter unit for blood and blood derivatives comprises a body defined by two injection-moulded half-shells of thermoplastic polymer material, there being present between said half-shells a cavity containing a filtering element having two opposing flat faces, an inlet opening and an outlet opening made on the opposing outer surfaces of said body communicating with said cavity. Each of said half-shells comprises a projecting perimetral flange, the flanges of the overlapping half-shells being welded together to form a flange of the body of the filter unit and connect the two half-shells together, the filtering element being wholly contained within the cavity of such body and pressed by shelves projecting into such cavity from each half-shell in the vicinity of its perimetral border and on the two opposing faces, said shelves retaining said filtering element in a stable position within cavity, said thermoplastic polymer material being yielding and semi-rigid.

Provided is an infusion system including: a liquid container that accommodates a blood derivative; a heating device that heats the blood derivative; an air bubble removal chamber that removes air bubbles in the blood derivative; a first flow path that connects the liquid container and the heating device to each other; a second flow path that connects the heating device and the air bubble removal chamber to each other; a third flow path that connects the air bubble removal chamber and an infusion unit to each other; a fourth flow path that connects the air bubble removal chamber and the liquid container to each other; a first pump provided in the first flow path; and a second pump provided in the third flow path. The heating device has a heating flow path where the blood derivative flows and a heat supply body that contacts the heating flow path.

Method for expanding adult stem cells from blood comprising the growth and deprogramming of the adult blood stem cells of a blood sample, by means of in vitro treatment of the blood sample with a PRP-based blood derivative product which includes autologous MCSF obtained by platelet lysis in a portion of the same autologous blood sample.

A collecting device for fluids for medical use may include a rigid container internally defining a first chamber having a fixed volume, an auxiliary container having a deformable portion defining internally thereof a second chamber having a variable volume as a function of a deformable portion thereof, a passage able to set the first and the second chamber in fluid communication, an inlet port connected to at least one of the containers, and an outlet port connected to at least one of the containers, as well as a bypass line for bypassing the device.